OPZELURA Drug Patent Profile

Which patents cover Opzelura, and when can generic versions of Opzelura launch?

Opzelura is a drug marketed by Incyte Corp and is included in one NDA. There are twenty-one patents protecting this drug and one Paragraph IV challenge.

This drug has three hundred and thirty-nine patent family members in forty-nine countries.

The generic ingredient in OPZELURA is ruxolitinib phosphate. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the ruxolitinib phosphate profile page.

DrugPatentWatch^® Generic Entry Outlook for Opzelura

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be May 20, 2031. This may change due to patent challenges or generic licensing.

There have been three patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for OPZELURA

International Patents:	339
US Patents:	21
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	65
Clinical Trials:	3
Drug Prices:	Drug price information for OPZELURA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for OPZELURA
What excipients (inactive ingredients) are in OPZELURA?	OPZELURA excipients list
DailyMed Link:	OPZELURA at DailyMed

See drug prices for OPZELURA

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for OPZELURA

NDA:

215309

Dosage:

CREAM;TOPICAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for OPZELURA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Sun Pharmaceutical Industries, Inc.	PHASE1
Incyte Corporation	Phase 3
Incyte Corporation	Phase 2

See all OPZELURA clinical trials

Pharmacology for OPZELURA

Drug Class	Janus Kinase Inhibitor Kinase Inhibitor
Mechanism of Action	Janus Kinase Inhibitors

Paragraph IV (Patent) Challenges for OPZELURA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
OPZELURA	Cream	ruxolitinib phosphate	1.5%	215309	1	2023-07-31

US Patents and Regulatory Information for OPZELURA

OPZELURA is protected by twenty-two US patents and three FDA Regulatory Exclusivities.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Incyte Corp	OPZELURA	ruxolitinib phosphate	CREAM;TOPICAL	215309-001	Sep 21, 2021		RX	Yes	Yes
Incyte Corp	OPZELURA	ruxolitinib phosphate	CREAM;TOPICAL	215309-001	Sep 21, 2021		RX	Yes	Yes					Y
Incyte Corp	OPZELURA	ruxolitinib phosphate	CREAM;TOPICAL	215309-001	Sep 21, 2021		RX	Yes	Yes
Incyte Corp	OPZELURA	ruxolitinib phosphate	CREAM;TOPICAL	215309-001	Sep 21, 2021		RX	Yes	Yes
Incyte Corp	OPZELURA	ruxolitinib phosphate	CREAM;TOPICAL	215309-001	Sep 21, 2021		RX	Yes	Yes					Y
Incyte Corp	OPZELURA	ruxolitinib phosphate	CREAM;TOPICAL	215309-001	Sep 21, 2021		RX	Yes	Yes					Y

International Patents for OPZELURA

When does loss-of-exclusivity occur for OPZELURA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Costa Rica

Croatia

Cyprus

Denmark

Ecuador

Eurasian Patent Organization

European Patent Office

Hong Kong

Hungary

Israel

Japan

Malaysia

Mexico

Montenegro

New Zealand

Peru

Philippines

Poland

San Marino

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering OPZELURA around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	2455382
South Korea	102402137
Spain	2714092
China	103214483
Ukraine	98449	ГЕТЕРОАРИЛЗАМІЩЕНІ ПІРОЛО[2,3-b]ПІРИДИНИ Й ПІРОЛО[2,3-b]ПІРИМІДИНИ ЯК ІНГІБІТОРИ ЯНУС-КІНАЗИ[ГЕТЕРОАРИЛЗАМЕЩЕННЫЕ ПИРРОЛО[2,3-b]ПИРИДИНЫ И ПИРРОЛО[2,3-b]ПИРИМИДИНЫ КАК ИНГИБИТОРЫ ЯНУС-КИНАЗЫ (HETEROARYL SUBSTITUTED PYRROLO[2,3-B]PYRIDINES AND PYRROLO[2,3-B]PYRIMIDINES AS JANUS KINASE INHIBITORS)
Taiwan	200728275	Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors

Supplementary Protection Certificates for OPZELURA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1966202	CA 2013 00005	Denmark
1966202	PA2013002,C1966202	Lithuania		PRODUCT NAME: RUXOLITINIBUM; REGISTRATION NO/DATE: EU/1/12/773/001-EU/1/12/773/003, 2 00120823
1966202	PA2013002	Lithuania
1966202	C 2013 005	Romania		PRODUCT NAME: RUXOLITINIB SAU O SARE FARMACEUTIC ACCEPTABILA AACESTUIA; NATIONAL AUTHORISATION NUMBER: RO EU/1/12/773/001, RO EU/1/12/773/002, RO EU/1/12/773/003; DATE OF NATIONAL AUTHORISATION: 20120823; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EMEA EU/1/12/773/001, EMEA EU/1/12/773/002, EMEA EU/1/12/773/003; DATE OF FIRST AUTHORISATION IN EEA: 20120823
1966202	2013/004	Ireland		PRODUCT NAME: RUXOLITINIB, OR A PHARMACEUTICALLY ACCEPTABLE SALT THREOF; REGISTRATION NO/DATE: EU/1/12/773/001-003 20120823
1966202	145 1-2013	Slovakia		FORMER OWNER: INCYTE CORPORATION, WILMINGTON, DE, US;

Market Dynamics and Financial Trajectory for Opzelura (Ruxolitinib Cream)

Last updated: February 19, 2026

What is the current market landscape for Opzelura?

Opzelura (ruxolitinib cream) is a topical Janus kinase (JAK) inhibitor approved by the FDA in June 2021 for atopic dermatitis in adults and children aged 12 and older. Its approval marked a shift in dermatology, expanding JAK inhibitor use from systemic to topical applications. As of 2023, the product targets a market estimated at $10 billion globally for atopic dermatitis alone, with rapid growth driven by increasing prevalence, unmet needs, and expanded indications.

The global atopic dermatitis market was valued at approximately $6 billion in 2022, projected to grow at a compound annual growth rate (CAGR) of 9% over the next five years. The topical JAK inhibitor segment is expected to capture a significant share due to efficacy and safety profiles relative to corticosteroids and immunomodulators.

How does Opzelura fit within the competitive environment?

Market positioning:

• First-in-class topical JAK inhibitor with high efficacy and favorable safety profile.
• Indications expand: Pivotal studies indicate potential for use in vitiligo, alopecia areata, and other inflammatory skin disorders, creating opportunities beyond atopic dermatitis.
• Competitors: Topical corticosteroids dominate early, with emerging drugs like Deucravacitinib (TYK2 inhibitor) and other JAK inhibitors (oral and topical).

Key competitors and pipeline status:

Drug	Manufacturer	Approval Status	Indication(s)	Market share (est.)	Remarks
Ruxolitinib (Opzelura)	AbbVie	Approved 2021	Atopic dermatitis	Leading in topical JAKs	First-mover advantage
Delgocitinib (JTE-052)	Japan-based	Approved in Japan, Phase 3 elsewhere	Atopic dermatitis	Limited outside Japan	Expanding global trials
Baricitinib (Olumiant)	Eli Lilly	Oral; FDA approval in other indications	Rheumatology, alopecia	Not topical	Competitive systemic JAK inhibitor
Deucravacitinib (Sotyktu)	BMS	Approved in 2022 for psoriasis	Psoriasis	Growing market	Oral, differs mechanism
Crisaborole (Eucrisa)	Pfizer	Approved for mild atopic dermatitis	Mild atopic dermatitis	Significant in OTC	Non-JAK topical, non-steroidal

What are the growth drivers and barriers for Opzelura?

Growth drivers:

1. Unmet medical needs: Persistent atopic dermatitis, especially in pediatric populations, lacks effective topical options.
2. Expanded indications: Pivotal trials for vitiligo and alopecia areata could unlock additional revenues, with FDA review scheduled for 2024.
3. Patient adherence: Topical formulations offer safety advantages over systemic JAK inhibitors, encouraging use.
4. Reimbursement and formulary inclusion: Positive payor coverage observed in early adopters, including specialty dermatology clinics.

Barriers:

1. Pricing and cost considerations: List prices around $2,500 per month challenge payor acceptance.
2. Adverse events and safety concerns: Long-term safety data remains limited versus established corticosteroids.
3. Market penetration challenges: Competition from corticosteroids and non-JAK topical agents.

What is the financial trajectory for Opzelura?

Revenue projections:

• 2022 (post-launch): Approximate sales of $200 million driven by pilot markets.
• 2023: Estimated sales reach $500 million with broader provider adoption.
• 2025: Sales should breach $1 billion assuming successful expansion into new indications and territories.

Revenue growth assumptions:

• CAGR of 31% from 2022-2025.
• Success in vitiligo and alopecia areata indications could contribute an additional 20-30% revenue boost by 2025.
• Pharmacovigilance and safety profile improvements may enable price premiums.

Cost structure:

• R&D Spend: Estimated $300 million annually, mainly for pipeline expansion.
• Manufacturing and supply chain costs: 15% of net revenue.
• Sales, marketing, and distribution: $250 million annually, focusing on specialist dermatology practices and advocacy groups.

Profitability outlook:

• Likely to achieve breakeven within 2-3 years post-launch with gross margins around 80%.
• Long-term profit margins may be constrained by pricing pressures and competitive dynamics.

What is the regulatory and commercial outlook?

• FDA approvals for vitiligo and alopecia areata expected in 2024, contributing to revenue diversification.
• Expansion efforts include collaborations in Asia, Europe, and Latin America.
• Pricing strategies will heavily influence market share and net margins.

Summary table: Financial and Market Potential

Metric	2022	2023	2024	2025
Estimated global sales (USD millions)	$200M	$500M	$800M	$1.2B
Estimated market share in atopic dermatitis	4%	8%	12%	15%
R&D investment (USD millions)	$300M/year	$300M	$300M	$300M
Launch of new indications (date)	2022	2023	2024	2024

Key Takeaways

• Opzelura is the first topical JAK inhibitor approved for atopic dermatitis, establishing a competitive advantage.
• Sales are expected to grow rapidly, driven by expanding indications and geographic reach.
• Pricing, safety, and market penetration will determine long-term financial success.
• Pipeline progress for vitiligo and alopecia areata may considerably diversify revenue streams.
• Competition remains strong from corticosteroids, other JAK inhibitors, and emerging topical agents.

FAQs

1. What are the primary drivers behind Opzelura's sales growth? The primary drivers include unmet patient needs for effective non-steroidal treatments, upcoming approvals for additional indications, and broader geographic expansion.

2. How does Opzelura compare to systemic JAK inhibitors? It offers similar efficacy with a topical formulation, potentially reducing systemic adverse events and improving patient adherence.

3. What challenges could limit Opzelura’s market penetration? Cost considerations, long-term safety concerns, and competition from corticosteroids and other topical agents.

4. What is the expected timeline for approval in additional indications? FDA review for vitiligo and alopecia areata is scheduled for 2024, possibly accelerating revenue growth from 2025 onward.

5. How does pricing impact Opzelura’s market success? The $2,500/month list price remains a barrier for some payers, potentially limiting uptake unless offset by demonstrated value and insurance coverage.

---

Sources:

[1] AbbVie. (2021). FDA approves Opzelura (ruxolitinib) cream for atopic dermatitis.
[2] MarketsandMarkets. (2023). Dermatology Therapeutics Market report.
[3] Evaluate Pharma. (2023). Topical dermatology drugs market forecast.
[4] FDA. (2022). Approved drugs for atopic dermatitis.
[5] Bloomberg Intelligence. (2023). Dermatology drugs market analysis.